Record Information |
---|
Version | 1.0 |
---|
Creation Date | 2016-05-22 03:57:52 UTC |
---|
Update Date | 2016-11-09 01:15:32 UTC |
---|
Accession Number | CHEM017136 |
---|
Identification |
---|
Common Name | Nifedipine |
---|
Class | Small Molecule |
---|
Description | |
---|
Contaminant Sources | - HMDB Contaminants - Urine
- STOFF IDENT Compounds
- ToxCast & Tox21 Chemicals
|
---|
Contaminant Type | Not Available |
---|
Chemical Structure | |
---|
Synonyms | Value | Source |
---|
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester | ChEBI | Adalat | ChEBI | Adapine | ChEBI | Coracten | ChEBI | Nifecard | ChEBI | Nifecor | ChEBI | Nifedipino | ChEBI | Nifedipinum | ChEBI | Nifedipres | ChEBI | Procardia | ChEBI | Afeditab CR | Kegg | BAY-a-1040 | HMDB | Cordipin | HMDB | Monohydrochloride, nifedipine | HMDB | Nifedipine monohydrochloride | HMDB | Nifedipine orion brand | HMDB | Nifedipine pfizer brand | HMDB | Nifedipine-gtis | HMDB | AWD pharma brand OF nifedipine | HMDB | BAY a 1040 | HMDB | Bayer brand OF nifedipine | HMDB | Korinfar | HMDB | Nifedipine krka brand | HMDB | Pfizer brand OF nifedipine | HMDB | Procardia XL | HMDB | Cordipine | HMDB | Fenigidin | HMDB | Orion brand OF nifedipine | HMDB | Adcock ingram brand OF nifedipine | HMDB | Corinfar | HMDB | KRKA brand OF nifedipine | HMDB | Nifangin | HMDB | Nifedipine bayer brand | HMDB | Nifedipine gtis | HMDB | Vascard | HMDB |
|
---|
Chemical Formula | C17H18N2O6 |
---|
Average Molecular Mass | 346.335 g/mol |
---|
Monoisotopic Mass | 346.116 g/mol |
---|
CAS Registry Number | 21829-25-4 |
---|
IUPAC Name | 3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
---|
Traditional Name | nifedipine |
---|
SMILES | COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC |
---|
InChI Identifier | InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 |
---|
InChI Key | HYIMSNHJOBLJNT-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. Dihydropyridinecarboxylic acids and derivatives are compounds containing a dihydropyridine moiety bearing a carboxylic acid group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyridines and derivatives |
---|
Sub Class | Hydropyridines |
---|
Direct Parent | Dihydropyridinecarboxylic acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Dihydropyridinecarboxylic acid derivative
- Nitrobenzene
- Nitroaromatic compound
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Benzenoid
- Methyl ester
- Enoate ester
- Alpha,beta-unsaturated carboxylic ester
- Vinylogous amide
- Organic nitro compound
- Carboxylic acid ester
- C-nitro compound
- Amino acid or derivatives
- Azacycle
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Carboxylic acid derivative
- Allyl-type 1,3-dipolar organic compound
- Secondary aliphatic amine
- Enamine
- Organic oxoazanium
- Secondary amine
- Organopnictogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Amine
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Not Available |
---|
Cellular Locations | Not Available |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Appearance | Not Available |
---|
Experimental Properties | Property | Value |
---|
Melting Point | Not Available | Boiling Point | Not Available | Solubility | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-00n0-1195000000-7e4e6770da078dff666a | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-0v4i-1691000000-c4842fe2c3070d6e90dd | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-0v4i-1691000000-c4842fe2c3070d6e90dd | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 40V, Positive | splash10-0fxy-0940000000-23744bb64d78de13acb0 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 20V, Positive | splash10-0udi-0490000000-93e13f20c2b96fd21829 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 10V, Positive | splash10-0gia-0192000000-7d81ad696e86cf9c1ebd | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 35V, Positive | splash10-0uy0-0492000000-a75cb00c5cb3e8f0c2c8 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0002-0009000000-9dada371e9f135db7acf | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0002-0009000000-568982a20ecb8f9fbb78 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0095-5196000000-a8be024a63e01b939a2a | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0002-0009000000-2d2fce579fb1386f8738 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0002-0009000000-5ebd1372ca17a57d813a | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0005-3095000000-ad731a5dda860a940c77 | Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Not Available |
---|
Mechanism of Toxicity | Not Available |
---|
Metabolism | Not Available |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | Not Available |
---|
Uses/Sources | Not Available |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB01115 |
---|
HMDB ID | HMDB0015247 |
---|
FooDB ID | Not Available |
---|
Phenol Explorer ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
BiGG ID | Not Available |
---|
BioCyc ID | Not Available |
---|
METLIN ID | Not Available |
---|
PDB ID | Not Available |
---|
Wikipedia Link | Nifedipine |
---|
Chemspider ID | 4330 |
---|
ChEBI ID | 7565 |
---|
PubChem Compound ID | 4485 |
---|
Kegg Compound ID | C07266 |
---|
YMDB ID | Not Available |
---|
ECMDB ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
MSDS | Not Available |
---|
General References | 1. Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996 Oct 23-30;276(16):1328-31. | 2. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366-72. | 3. Varon J, Marik PE: Clinical review: the management of hypertensive crises. Crit Care. 2003 Oct;7(5):374-84. Epub 2003 Jul 16. | 4. Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H: Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther. 2005 Apr;30(2):153-8. | 5. Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, van Dalen FJ, Lubsen J: Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006 Feb;20(1):45-54. | 6. Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, Gunduz MG, Safak C, Yamada S: Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol Pharm Bull. 2008 Mar;31(3):473-9. |
|
---|